Dipna Pharmachem Limited

Healthcare — Pharmaceutical Retailers · BSE

₹3.97−₹0.08 (−1.98%)

DalalBaazaar Score

51 / 100

🟡 Moderate

Verdict

CAUTION

Risk

Low

Driven by micro-cap size, which brings thin liquidity, falling profits.

In simple words: The business is earning a fairly low return on the money invested in it, but sales are shrinking. The direction of profits is the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:04 pm

Caution warranted. Multiple fundamental metrics — flagged in red below — point to either valuation stretch, leverage risk, or weakening profitability. This doesn't mean avoid the stock outright, but it does mean the burden of proof is on the growth story to justify the current price.

Understanding the Business

Company site ↗

The 60-second version of Dipna Pharmachem Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Dipna Pharmachem Limited imports, trades in, and exports pharmaceutical products primarily in India. It offers industrial chemicals, pharmaceutical raw materials, excipients, solvents, active pharmaceutical ingredients, formulations, and intermediates.

IndustryPharmaceutical Retailers

SectorHealthcare

Annual revenue₹125 Cr

How does it make money?

Turns over ₹125 Cr a year. Of every ₹100 of sales, about ₹1 reaches shareholders as profit, with ₹3 left at the operating level before interest, tax and depreciation.

EBITDA margin3.0%

Net margin0.8%

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, DR. REDDY S LABORATORIES, CIPLA LTD, DIVI S LABORATORIES LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

SUN PHARMACEUTICAL IND LP/E 34.9x · ROE 14.5%

DR. REDDY S LABORATORIESP/E 31.0x · ROE 8.8%

CIPLA LTDP/E 31.8x · ROE 9.8%

DIVI S LABORATORIES LTDP/E 83.0x · ROE 17.5%

What is its competitive advantage?Little sign of one

Returns on capital of 5.2% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

ROCE5.2%

ROE5.2%

Peer median ROE14.5%

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +25% while net margin moved -15% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+25%

Margin effect-15%

DalalBaazaar Score

51/ 100

Moderate

Weighted across six categories. Every point is explained below.

✗ ROE of 5.2% is weak

Quality vs. Valuation

Company Quality

44/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

77/ 100

Cheap

What you are being asked to pay, ignoring how good the business is.

Optically cheap, but the underlying business scores poorly. Cheap-and-weak is what a value trap looks like from the outside — the low price may be deserved.

Historical Valuation

Current P/E

9.7x

3Y Median

16.0x

40 monthly readings · mean 18.6x · range 4.0x–51.8x

Sector Median

33.3x

median of 4 sector peers

🟢Current valuation is approximately 39% below its 3y median of 16.0x. Cheaper than its own history, which is worth a reason too: the market may be pricing in something the backward-looking numbers do not show.

🟢Against its sector it trades 71% below the peer median of 33.3x.

vs. its own history

Cheap

16.0x median over 40 months · -39%

vs. sector peers

Cheap

33.3x median of 4 peers · -71%

vs. generic bands

Cheap

Below 15x

P/E (Trailing)

9.7x

P/B

0.16x

EV/EBITDA

6.1x

PEG

4.36

Dividend Yield

None

What's Good / What's Bad

🟢 What's Going Well4

Debt is being paid down
Total debt is down 17% over 3 years.
Valuation below its historical average
At 9.7x the stock trades 39% below its own median of 16.0x.
Very low debt
Debt/Equity of 0.21x leaves the balance sheet with plenty of headroom.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention3

Free cash flow is negative
The business is not currently covering its capital spending from operations.
Receivables growing faster than sales
Receivables are up 68% against revenue growth of 25% — customers are taking longer to pay.
Inventory building faster than sales
Inventory is up 123% against revenue growth of 25% — stock may not be moving.

Red Flags

6 items require attention · 3 high · 3 watch

🔴Thin interest coverageFinancial
Operating profit covers interest only 1.6x — little room if earnings dip.
🔴Free cash flow negative for 4 yearsFinancial
The business has not covered its capital spending from operations for several years running, which has to be funded externally.
🔴Inventory building faster than salesFinancial
Inventory up 123% against revenue up 25% — stock may not be moving.
🟡Interest coverage is deterioratingFinancial
Cover has fallen from 3.4x to 1.6x.
🟡Receivables growing faster than salesFinancial
Receivables up 68% against revenue up 25% — sales are being booked faster than they are collected.
🟡Shareholders have been dilutedOwnership
Shares outstanding are up 80% over 3 years — each existing share owns a smaller slice of the company.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Deleveraging frees up earnings
Debt is down 17% over 3 years. Every rupee of interest not paid drops to the bottom line, so profit can grow even if revenue does not.
Priced below its own history
The stock trades 39% below its own median multiple. If the business performs as it has and simply re-rates back to normal, that gap is return on its own.
Cheaper than its peers
It trades 71% below the sector median. Either the market sees a problem the numbers do not show, or the discount closes.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

The debt load needs earnings to hold up
Debt is 3.5x EBITDA. At that level a downturn in earnings turns a manageable balance sheet into a refinancing problem, and lenders get paid before shareholders.
Sales are being booked faster than collected
Receivables are up 68% against revenue up 25%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
Growth barely outpaces inflation
Revenue compounding at 7.7% a year is close to the rate prices rise, so the business is gaining little ground in real terms. That leaves the share price dependent on a re-rating rather than on earnings growth.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above 1%✓ 3.0%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Debt / EBITDA falls below 3x✗ 3.5x
Already stretched, so this is a reduction target rather than a level to hold. Around 3x is where lenders typically start attaching conditions.
3Free cash flow remains positive✗ -₹18 Cr
Profit that never becomes cash eventually stops being profit.
4Interest cover stays above 3x✗ 1.6x
How much operating profit can fall before interest stops being comfortably covered.
5Revenue growth stays above 6% a year✓ 7.7% CAGR
Latest reported year was -88.2%. The bar is set below the established compounding rate, so ordinary variation does not trip it.

Investment Checklist

5 / 11 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✗ Revenue growing year-over-year
✗ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

5 good · 2 neutral · 4 weak

Market Cap

₹10 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

9.7x

Cheap

Cheap against the generic band

P/B Ratio

0.16x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹0.41

Profitable

Profitable on a per-share basis

ROE

5.2%

Weak

Weak capital efficiency

ROCE

5.2%

Weak

Low return on total capital employed

Debt/Equity

0.21x

Low

Conservative leverage

Revenue Growth (YoY)

-88.2%

Shrinking

Sales are contracting

Profit Growth (YoY)

-48.5%

Falling

Profits are shrinking

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

₹34 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

CMP

₹3.97

ROA

1.8%

Weak

Assets generate little profit

Operating Margin

21.2%

Good

Healthy core-business profitability

Net Margin

2.0%

Weak

Very little revenue reaches the bottom line

Current Ratio

1.16

Adequate

Adequate, but no real cushion

Beta (vs Nifty)

0.00

Defensive

Steadier than the market

52W Range Position

Near low

Near its 52-week low

Technical Snapshot

SMA 20 / SMA 50

4.3 / 4.9

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

29.1

Oversold zone

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹100 Cr	₹164 Cr	₹129 Cr	₹125 Cr	+7.7%
EBITDA	₹2 Cr	₹3 Cr	₹5 Cr	₹4 Cr	+15.9%
EBITDA Margin	2.4%	2.1%	3.9%	3.0%	—
PAT (Net Profit)	₹1 Cr	₹1 Cr	₹3 Cr	₹1 Cr	+2.2%
EPS	₹0.76	₹0.45	₹1	—	—
ROE	3.7%	2.9%	6.8%	1.6%	—
ROCE	6.6%	6.9%	10.6%	5.2%	—
Total Debt	₹16 Cr	₹19 Cr	₹17 Cr	₹13 Cr	-6.0%
Free Cash Flow	-₹21 Cr	-₹5 Cr	-₹9 Cr	-₹18 Cr	—

🟢 Revenue has grown at 7.7% a year over 3 years.

🟢 EBITDA has grown at 15.9% a year over 3 years.

🟡 EBITDA Margin has held roughly flat at 3.0% over 3 years.

🟢 PAT (Net Profit) has grown at 2.2% a year over 3 years.

🔴 ROE has fallen from 3.7% to 1.6% over 3 years (-2.2 pts).

🔴 ROCE has fallen from 6.6% to 5.2% over 3 years (-1.5 pts).

🟢 Total Debt has shrunk at 6.0% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹206 Cr

Total Liabilities

₹143 Cr

Total Debt

₹13 Cr

Cash & Equivalents

₹1 Cr

Operating Cash Flow

-₹18 Cr

Capex

-₹0 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

52.6%

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
DR. REDDY S LABORATORIES	31.0x	8.8%
CIPLA LTD	31.8x	9.8%
DIVI S LABORATORIES LTD	83.0x	17.5%

Recent News

1 positive5 general

Compare with

Equitymaster, 15 Oct

Dipna Pharmachem FY26 net profit rises 170% to ₹263.19 lakh

scanx.trade, 02 JulResults

🟢Potentially positiveReported improvement. Check whether it came from volume, price or a one-off item before treating it as a trend.

Dipna Pharmachem IPO GMP, Price, Review, Allotment & Analysis

IPO Watch, 11 Sept

Dipna Pharmachem Ltd. Peer Comparison – Compare with Others

Value Research, 01 Sept

Dipna Pharmachem Ltd IPO saw a 132% increase in revenue, predicting a good future for the stock market

Zee Business, 25 Aug

Pharma Penny Stocks: Best Pharmaceutical Penny Stocks In India

Alice Blue, 11 Apr

Watch Items

Revenue growth is negative (-88.2%) on the latest reported period — check if this is one-off or a trend.
Trading very close to its 52-week low — worth checking whether this reflects a temporary setback or a structural problem.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
RSI is in oversold territory — could mean either a bargain or a stock still falling for good reason. Check the 'why' before assuming reversal.

DalalBaazaar Thesis

🔴Business QualityWeak7.5/20

🟢Financial HealthStrong13.7/20

🔴GrowthWeak7.4/20

🔴ProfitabilityWeak4.5/15

🟢ValuationAttractive13.2/15

🔴RiskHigh4.4/10

Cheap, but for a reason

The low price is the whole case here, and the business underneath scores poorly. Cheap-and-weak is what a value trap looks like from the outside — it needs a specific reason the numbers are about to improve, not just the observation that they are low. 3 high-severity red flags sit above this conclusion and should be read first.

This thesis breaks if

✓EBITDA margin holds above 1%3.0%
✗Debt / EBITDA falls below 3x3.5x
✗Free cash flow remains positive-₹18 Cr
✗Interest cover stays above 3x1.6x
✓Revenue growth stays above 6% a year7.7% CAGR